학술논문
AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: Improvement in cognitive function and reduction of antipsychotic-side effects in rodents
Document Type
Article
Author
Source
In: Psychopharmacology . (Psychopharmacology, May 2011, 215(1):149-163)
Subject
Language
English
ISSN
00333158
14322072
14322072